NCT05992610招募中不适用
Induction Treatment in Patients With Squamous Cell Carcinoma (SCC) of the Head and Neck Region Consisting Concomitant Chemotherapy and Low-dose Ionizing Radiotherapy
Maria Sklodowska-Curie National Research Institute of Oncology2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2022年2月17日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- Overall survival time (OS)
研究概览
简要总结
Non-commercial clinical study to assess:
- efficacy of iCHRTL in patients with advanced squamous cell carcinoma of oral cavity, pharynx carcinoma, larynx carcinoma or paranasal sinus carcinoma.
- tolerability of iCHRTL in patients with advanced squamous cell carcinoma of oral cavity, pharynx carcinoma, larynx carcinoma or paranasal sinus carcinoma.
- molecular and biochemical effect of low doses of ionizing radiation.
详细描述
40 patients with squamous cell carcinoma of oral cavity, pharynx, larynx or paranasal sinuses in stage III or IV, previously not treated for this reason and eligible for induction chemotherapy.
Study treatment:
Induction phase:
Chemotherapy based on carboplatin 6 area under the curve (AUC) + paclitaxel 75 mg/m2 carboplatin 6 AUC 30-minute infusion on D: 1 (maximum carboplatin dose is 700 mg) paclitaxel 75 mg/m2 1-hour infusion on D: 1, 8, 15
Radiotherapy:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with squamous cell carcinoma of oral cavity, upper, middle, lower pharynx carcinoma, larynx carcinoma or paranasal sinus carcinoma in advanced stage III or IV and previously not treated for this reason.
- •Severity of the disease: N1 > 2 cm, N2, N3 ; T2, T3, T4, M0
- •Patient eligible for radical treatment with induction chemotherapy (at least in good general condition (ZUBROD 0-1) with no significant additional diseases disqualifying from induction chemotherapy).
- •Written informed consent form to the proposed therapeutic scheme.
- •Age over 18 years.
排除标准
- •Subjects with known or suspected hypersensitivity to any of the study mediations.
- •Baseline values for the following parameters (in the screening phase):
- •Creatinine >2,0 x upper limit of normal (ULN) - unless creatinine clearance is normal
- •Total bilirubin >1,5 x ULN (except for hyperbilirubinemia caused by Gilbert's syndrome)
- •Alanine Transaminase (ALT) activity, Aspartate Transaminase (ASPAT) >2,5 x ULN
- •Alkaline phosphatase activity >2,5 x ULN
- •Prior treatment with any unauthorized medication or investigational treatment before the 5 half-lives of that substance or 4 weeks prior to study entry (a longer period of time should be assumed), or subjects currently enrolled to other interventional clinical trials.
- •Concomitant malignancy or history of a malignancy with a significant potential impact to tolerability or effectivity of iCHRTL.
- •Chronic or active infection requiring antibiotic, antifungal or antiviral treatment, such as, but not limited to: chronic kidney infection, chronic respiratory tract infection with bronchospasm, tuberculosis or active hepatitis C virus infection.
- •History of significant cerebrovascular disease within 6 months or currently symptomatic or its implications.
- •Human Immunodeficiency Virus (HIV) infection.
- •Clinically significant heart disease including unstable angina, myocardial infarction within 6 months prior to study entry, severe congestive circulatory failure class New York Heart Association (NYHA) III-IV, arrhythmias unless it is treated, except for collateral contractions or minimal conduction disorders.
- •Significant concomitant disease that cannot be treated, such as, but not limited to kidney, liver, gastrointestinal, endocrine system, respiratory, neurological and brain diseases and mental illnesses that may pose a risk to the patient in the opinion of the investigator.
- •Active hepatitis B virus (HBV) infection, defined as having a positive Hepatitis B surface antigen (HBsAg) test. Moreover, in case of a negative HBsAg test result but a positive Hepatitis B core Antibody (HBcAb) test result (regardless of HBsAb status), HBV DNA should be determined and in case of a positive result the patient cannot be included to the study.
- •Active hepatitis C virus (HCV) infection, defined as having a positive Hepatitis C Antibody (HCAb) test, in which case Hepatitis C virus recombinant immunoblot assay (HCV RIBA) should be determined from the same sample to confirm the result.
- •Pregnancy or breastfeeding (women of childbearing potential must have pregnancy test performed during screening).
- •Women of childbearing potential, including women whose last menstrual period occurred in less than one year before screening, who cannot or do not want to use adequate contraception methods from the beginning of the study until 6 months after the last dose of study drug. Adequate contraception is defines as the use of oral hormonal contraceptives, an intrauterine device, a double barrier method or sexual abstinence.
- •Men who cannot or do not want to use adequate contraception methods from the beginning of the study until 6 months after the last dose of study medication.
- •Patients who cannot or do not want to adhere to the study Protocol.
结局指标
主要结局
Overall survival time (OS)
时间窗: Date of treatment start - to 3 years
Rate of death within time from treatment start to 3 years
Distant metastasis rate
时间窗: 3 years post-induction
Rate of patients with distant metastases
Objective response rate (ORR) after induction
时间窗: 3 years post-induction
Complete+partial response in percent
Loco-regional control (LRC) rate
时间窗: 3 years post-induction
Rate of local lesions CR+PR+SD
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
招募中
1 期
Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCCCarcinoma, Squamous CellNCT03370406Melissa Pugliano-Mauro30
已完成
不适用
Phase II study of TS-1 + CPT-11 for squamous cell lung cancer previously treated with platinumon-small cell lung cancer (squamous cell carcinoma)JPRN-UMIN000006065orth Japan Lung Cancer Group30
进行中（未招募）
2 期
MIT-001 for Prevention of CCRT-Induced OM in HNSCC PatientsHead and Neck Squamous Cell CarcinomaOral MucositisNCT04651634MitoImmune Therapeutics60
招募中
不适用
Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell CarcinomaHead and Neck Squamous Cell Carcinoma (HNSCC)NCT06630780Sun Yat-sen University50
进行中（未招募）
4 期
A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or ScalpKeratosis, ActinicNCT05387525Almirall, S.A.447